Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
U.S. Food and Drug Administration allowed Black Diamond’s investigational new drug application for its lead product candidate BDTX-189 in December; Company initiated Phase 1/2 clinical trial and has subsequently started enrolling and dosing patients Cash …